Special Issue

Drug Discovery in the Fight Against Bacterial Infections

Message from the Guest Editors

The increasing number of infections caused by antibiotic-resistant bacterial pathogens over recent decades has become a critical global health problem. A recent report on the global burden of bacterial antimicrobial resistance (AMR) in 2019 stated that 4.95 million deaths were associated with AMR bacteria, including 1.27 million directly attributed deaths. If a sustained effort to contain AMR is not undertaken, it is anticipated that by the year 2050, or before, there will have been 10 million deaths caused by untreatable bacterial infections. Therefore, new antimicrobials are urgently needed. In 2021, the WHO identified only 27 antibiotics in clinical development that might address the priority pathogens, of which only two fulfil all of the criteria to be considered fully innovative: no cross-resistance, of a new chemical class, and with a new target and new mechanism of action.

Guest Editors

Dr. Sara M. Soto

Barcelona Institute for Global Health (ISGlobal), Universitat de Barcelona, 08036 Barcelona, Spain

Prof. Dr. Raquel G. Soengas

Department of Organic and Inorganic Chemistry, University of Oviedo, Julián Clavería, 33006 Oviedo, Spain

Deadline for manuscript submissions

30 November 2026

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed

mdpi.com/si/222830

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed

mdpi.com/journal/antibiotics

MDPI

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)